Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 9889204
Polymeric antibiotics
granted -
US 9889092
Low density lipoprotein nanocarriers for targeted delivery of omega-3 polyunsaturated fatty acids to cancer
granted -
US 9889182
Assisted enzyme replacement therapy
granted -
US 9889156
Method for treating noise-induced hearing loss (NIHL)
granted -
US 9889081
Aldehyde dehydrogenase inhibitors as novel depigmenting agents
granted -
US 9888673
Genetically modified cells, tissues, and organs for treating disease
granted -
US 9889071
Calcium sulfate-resin hybrid materials and methods of using and making the same
granted -
US 9890216
Antibodies with engineered IgG Fc domains
granted -
US 9890221
Cellulose ethers esterified with dicarboxylic acid
granted -
US 9884114
Methods of rational nicotine hapten design and uses thereof
granted -
US 9884097
Fungal immunogens and related materials and methods
granted -
US 9884070
Selective high-affinity polydentate ligands and methods of making such
granted -
US 9884096
Compositions and methods related to graft versus host disease and treatments thereof
granted -
US 9885051
Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogenicity and/or safety
granted -
US 9885018
High efficiency reprogramming of fibroblasts into cardiomyocytes
granted -
US 9884863
STAT3 inhibitor
granted -
US 9884866
Immunomodulators and immunomodulator conjugates
granted -
US 9884820
Pro-neurogenic compounds
granted -
US 9885072
High molecular weight heparosan polymers and methods of production of use thereof
granted -
US 9884841
Small molecule inhibitors of Mcl-1 and uses thereof
granted -
US 9885014
Re-conditioned serum-free culture medium composition obtained by culturing mammalian cells in Fibromodulin
granted -
US 9878002
Compositions and methods involving endogenous retrovirus proteins
granted -
US 9879260
Micro-RNA regulation of bone loss
granted -
US 9878137
Bioactive agent delivery devices and methods of making and using the same
granted -
US 9878045
Triorthogonal reagents for dual protein conjugation
granted -
US 9878033
Immunogenic peptides for treatment of herpes simplex virus infection and conditions
granted -
US 9878010
Methods of treating metabolic disorders
granted -
US 9878006
Treatment of obesity and obesity related disorders by pharmalogical targeting of Kv1.3 potassium channels
granted -
US 9877937
Compounds and methods for treating aberrant adrenocortical cell disorders
granted -
US 9872953
Nitric oxide delivery devices
granted -
US 9873718
Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics
granted -
US 9872926
Multicolored pH-activatable fluorescence nanoplatform
granted -
US 9868777
CMV neutralizing antigen binding proteins
granted -
US 9868961
Methods and compositions for localized secretion of anti-CTLA-4 antibodies
granted -
US 9868736
Deubiquitinase inhibitors and methods for use of the same
granted -
US 9867845
Vectors for delivery of agents across biological membranes
granted -
US 9867778
Controlled release antimicrobial compositions and methods for the treatment of otic disorders
granted -
US 9867866
Methods for diagnosing, prognosing and treating muscular dystrophy
granted -
US 9862928
Generation of natural killer cells and lymphoid tissue inducer-like (LTi-like) NK-22 cells
granted -
US 9862684
Modulation of K2P channels
granted -
US 9862748
Peptide compounds and methods of production and use thereof
granted -
US 9862746
Compositions and methods relating to hindering DOT1L recruitment by MLL-fusion proteins
granted -
US 9862693
Compounds and methods of treating cancer
granted -
US 9861600
Methods and compositions for treating and identifying compounds to treat age-related macular degeneration treatment
granted -
US 9855368
Bone morphogenic protein binding peptide
granted -
US 9856283
Thiosaccharide mucolytic agents
granted -
US 9856273
ETP derivatives
granted -
US 9856206
Oligo-benzamide compounds and their use
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory